aspirin has been researched along with Dyslipidemia in 49 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 9.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV." | 9.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia." | 9.14 | Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 8.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 7.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 7.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia." | 7.83 | Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016) |
| "To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia." | 7.79 | Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 5.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors." | 5.19 | Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014) |
| "Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia." | 5.14 | Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. ( Jiang, P; Kashyap, ML; Krause, SL; Lewin, AJ; Padley, RJ; Thakkar, RB, 2009) |
| "A prospective, clinical trial of 35 patients with mixed dyslipidemia who were treated with niacin-ER and SV." | 5.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "The Japanese Primary Prevention Project (JPPP) is a multicenter, open-label, randomized, parallel-group trial that is evaluating primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus." | 5.14 | Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamada, N; Yamazaki, T; Yokoyama, K, 2010) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 4.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 3.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project." | 3.91 | Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| " Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions." | 3.88 | Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. ( Chamberlain, JJ; Johnson, EL; Leal, S; Peterson, L; Rhinehart, AS; Shubrook, JH, 2018) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 3.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia." | 3.83 | Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016) |
| "To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia." | 3.79 | Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013) |
| "Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup." | 2.90 | Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| " An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill." | 2.79 | The evening versus morning polypill utilization study: the TEMPUS rationale and design. ( Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014) |
| "Aspirin, which has been shown to reduce the local production of gall bladder mucins (mucosal or parietal factors of gallstone formation) in animal experimental models, does not appear to reduce the risk of symptomatic gallstones disease when tested alone." | 2.48 | Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. ( Cariati, A; Piromalli, E, 2012) |
| " There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements." | 2.45 | Mechanisms of flushing due to niacin and abolition of these effects. ( Arora, R; Sood, A, 2009) |
| "Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life." | 2.45 | Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Cardiovascular diseases are the major cause of death and a significant cause of disability in the Western world and more recently threaten to pose an increasing health burden on developing nations." | 2.43 | Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. ( Grewal, J; Lonn, E, 2006) |
| "In Western European countries, acute ischemic stroke (AIS) remains the third leading cause of death." | 1.62 | Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy. ( Freitas-Silva, M; Medeiros, R; Nunes, JPL, 2021) |
| "7%), all at low dosage levels." | 1.35 | [Prescription patterns for antilipidemic drugs in a group of Colombian patients]. ( Machado, JE; Mesa, G; Moncada, JC, 2008) |
| "But aspirin therapy was used in only 35 cases (32." | 1.33 | The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM. ( Limpawattana, P; Mahankkanukrauh, A; Sawanyawisuth, K; Wongvipaporn, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (36.73) | 29.6817 |
| 2010's | 28 (57.14) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, M | 1 |
| Lee, S | 1 |
| Han, YM | 1 |
| Lee, YJ | 1 |
| Jang, YN | 1 |
| Kim, HM | 1 |
| Seo, HS | 1 |
| Jung, TW | 1 |
| Jeong, JH | 1 |
| Freitas-Silva, M | 1 |
| Medeiros, R | 1 |
| Nunes, JPL | 1 |
| Zuo, HJ | 1 |
| Wang, WH | 1 |
| Deng, LQ | 1 |
| Su, JL | 1 |
| Chamberlain, JJ | 1 |
| Johnson, EL | 1 |
| Leal, S | 1 |
| Rhinehart, AS | 1 |
| Shubrook, JH | 1 |
| Peterson, L | 1 |
| Sugawara, M | 5 |
| Goto, Y | 2 |
| Yamazaki, T | 5 |
| Teramoto, T | 5 |
| Oikawa, S | 6 |
| Shimada, K | 5 |
| Uchiyama, S | 5 |
| Ando, K | 5 |
| Ishizuka, N | 5 |
| Murata, M | 5 |
| Yokoyama, K | 5 |
| Uemura, Y | 2 |
| Ikeda, Y | 5 |
| Faggiano, P | 1 |
| Fattirolli, F | 1 |
| Frisinghelli, A | 1 |
| Piccioli, L | 1 |
| Dasseni, N | 1 |
| Silverii, MV | 1 |
| Albricci, L | 1 |
| D'Ambrosio, G | 1 |
| Garrì, R | 1 |
| Esposito, L | 1 |
| Giallauria, F | 1 |
| Cheng, F | 1 |
| Li, W | 1 |
| Zhou, Y | 1 |
| Li, J | 1 |
| Shen, J | 1 |
| Lee, PW | 1 |
| Tang, Y | 1 |
| Lin, SE | 1 |
| Huang, JP | 1 |
| Wu, LZ | 1 |
| Wu, T | 1 |
| Cui, L | 1 |
| Stolarz-Skrzypek, K | 1 |
| Bednarski, A | 1 |
| Drozdz, D | 1 |
| Czarnecka, D | 1 |
| Bobolea, I | 1 |
| Cabañas, R | 1 |
| Jurado-Palomo, J | 1 |
| Fiandor, A | 1 |
| Quirce, S | 1 |
| De Kam, PJ | 1 |
| Luo, WL | 1 |
| Wenning, L | 1 |
| Ratcliffe, L | 1 |
| Sisk, CM | 1 |
| Royalty, J | 1 |
| Radziszewski, W | 1 |
| Wagner, JA | 1 |
| Lai, E | 1 |
| Barbieri, L | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Marino, P | 1 |
| De Luca, G | 1 |
| Paixao, AR | 1 |
| Enriquez, JR | 1 |
| Wang, TY | 1 |
| Li, S | 1 |
| Berry, JD | 1 |
| Khera, A | 1 |
| Das, SR | 1 |
| de Lemos, JA | 1 |
| Kontos, MC | 1 |
| Minematsu, K | 1 |
| Matsumoto, M | 1 |
| Hagström, E | 1 |
| Roe, MT | 1 |
| Hafley, G | 1 |
| Neely, ML | 1 |
| Sidhu, MS | 1 |
| Winters, KJ | 1 |
| Prabhakaran, D | 1 |
| White, HD | 1 |
| Armstrong, PW | 1 |
| Fox, KA | 1 |
| Ohman, EM | 1 |
| Boden, WE | 1 |
| Lou, G | 1 |
| Chen, J | 1 |
| Xia, Y | 1 |
| Yonetsu, T | 1 |
| Lee, T | 1 |
| Murai, T | 1 |
| Kanno, Y | 1 |
| Hamaya, R | 1 |
| Ichijo, S | 1 |
| Niida, T | 1 |
| Hada, M | 1 |
| Araki, M | 1 |
| Matsuda, J | 1 |
| Usui, E | 1 |
| Hoshino, M | 1 |
| Kanaji, Y | 1 |
| Kakuta, T | 1 |
| Engberding, N | 1 |
| Wenger, NK | 1 |
| Federman, DG | 1 |
| Shelling, M | 1 |
| Prodanovich, S | 1 |
| Gunderson, CG | 1 |
| Kirsner, RS | 1 |
| Thakkar, RB | 1 |
| Kashyap, ML | 1 |
| Lewin, AJ | 1 |
| Krause, SL | 1 |
| Jiang, P | 1 |
| Padley, RJ | 1 |
| Philipp, S | 1 |
| Böse, D | 1 |
| Wijns, W | 1 |
| Marso, SP | 1 |
| Schwartz, RS | 1 |
| König, A | 1 |
| Lerman, A | 1 |
| Garcia-Garcia, HM | 1 |
| Serruys, PW | 1 |
| Erbel, R | 1 |
| Sood, A | 1 |
| Arora, R | 1 |
| Yamada, N | 1 |
| Jacobson, TA | 1 |
| Frisbee, JC | 1 |
| Goodwill, AG | 1 |
| Stapleton, PA | 1 |
| Frisbee, SJ | 1 |
| d'Audiffret, AC | 1 |
| Salgado, BJ | 1 |
| Salgado, JV | 1 |
| Dos Santos, AM | 1 |
| Casulari, LA | 1 |
| Poisson, S | 1 |
| Johnston, SC | 1 |
| Yameogo, NV | 1 |
| Ndiaye, MB | 1 |
| Mbaye, A | 1 |
| Bennani, R | 1 |
| Kagambega, LJ | 1 |
| Bodian, M | 1 |
| Diao, M | 1 |
| Sarr, M | 1 |
| Kane, A | 1 |
| Ba, SA | 1 |
| Shinohara, Y | 1 |
| Cariati, A | 1 |
| Piromalli, E | 1 |
| Ward, DR | 1 |
| Novak, E | 1 |
| Scott-Douglas, N | 1 |
| Brar, S | 1 |
| White, M | 1 |
| Hemmelgarn, BR | 1 |
| Lafeber, M | 1 |
| Grobbee, DE | 1 |
| Bots, ML | 1 |
| Thom, S | 1 |
| Webster, R | 1 |
| Rodgers, A | 1 |
| Visseren, FL | 1 |
| Spiering, W | 1 |
| Papp, E | 1 |
| Havasi, V | 1 |
| Bene, J | 1 |
| Komlosi, K | 1 |
| Czopf, L | 1 |
| Magyar, E | 1 |
| Feher, C | 1 |
| Feher, G | 1 |
| Horvath, B | 1 |
| Marton, Z | 1 |
| Alexy, T | 1 |
| Habon, T | 1 |
| Szabo, L | 1 |
| Toth, K | 1 |
| Melegh, B | 1 |
| Haines, ST | 1 |
| Fuke, DC | 1 |
| Lender, D | 1 |
| Rodgers, PT | 1 |
| Sysko, SK | 1 |
| Sawanyawisuth, K | 1 |
| Limpawattana, P | 1 |
| Mahankkanukrauh, A | 1 |
| Wongvipaporn, C | 1 |
| Oberwittler, H | 1 |
| Baccara-Dinet, M | 1 |
| Kakafika, AI | 2 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 2 |
| Athyros, VG | 2 |
| Mikhailidis, DP | 2 |
| Lonn, E | 1 |
| Grewal, J | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Kotake, H | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 1 |
| Liao, JK | 1 |
| Faraday, N | 1 |
| Yanek, LR | 1 |
| Mathias, R | 1 |
| Herrera-Galeano, JE | 1 |
| Vaidya, D | 1 |
| Moy, TF | 1 |
| Fallin, MD | 1 |
| Wilson, AF | 1 |
| Bray, PF | 1 |
| Becker, LC | 1 |
| Becker, DM | 1 |
| Tziomalos, K | 1 |
| Pagourelias, ED | 1 |
| Skaperdas, A | 1 |
| Hatzitolios, A | 1 |
| Machado, JE | 1 |
| Moncada, JC | 1 |
| Mesa, G | 1 |
| Masanauskiene, E | 1 |
| Naudziūnas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Meal Timing on Neurovascular Control in Adults[NCT04133701] | 34 participants (Actual) | Interventional | 2022-02-02 | Completed | |||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia[NCT01012219] | Phase 1 | 36 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia[NCT00626392] | Phase 3 | 277 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill[NCT01506505] | 78 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days.~The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable.~Period 3 was not analyzed as bleeding time was not an objective for this part of the study." (NCT01012219)
Timeframe: Day 8
| Intervention | Seconds (Least Squares Mean) |
|---|---|
| Clopidogrel + Aspirin +Laropiprant | 478 |
| Clopidogrel + Aspirin | 389 |
Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Number of Events per Subject per Week (Mean) |
|---|---|
| Any Acetylsalicylic Acid | 0.3 |
| No Acetylsalicylic Acid | 0.8 |
Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Any Acetylsalicylic Acid | 3.1 |
| No Acetylsalicylic Acid | 5.1 |
The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: From Baseline to end of Week 1
| Intervention | Percentage of Subjects (Number) | |||||
|---|---|---|---|---|---|---|
| None | Mild | None/mild | Moderate | Severe | Very severe | |
| Any Acetylsalicylic Acid | 57 | 28 | 85 | 11 | 4 | 1 |
| No Acetylsalicylic Acid | 48 | 24 | 71 | 17 | 8 | 4 |
The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated. (NCT00626392)
Timeframe: 4 weeks
| Intervention | Percentage of Subjects (Number) | |||||
|---|---|---|---|---|---|---|
| None | Mild | None/Mild | Moderate | Severe | Very severe | |
| Any Acetylsalicylic Acid | 30 | 28 | 58 | 28 | 11 | 4 |
| No Acetylsalicylic Acid | 15 | 14 | 30 | 35 | 23 | 13 |
17 reviews available for aspirin and Dyslipidemia
| Article | Year |
|---|---|
[Prevention of atherosclerosis in children--the role of statins and aspirin].
Topics: Adult; Aspirin; Atherosclerosis; Child; Comorbidity; Diabetes Mellitus; Dyslipidemias; Humans; Hydro | 2013 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
Psoriasis: an opportunity to identify cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F | 2009 |
Mechanisms of flushing due to niacin and abolition of these effects.
Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hypolipidemic Agents; Indoles; Nia | 2009 |
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Topics: Aspirin; Attitude to Health; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2010 |
Prevention of stroke following transient ischemic attack.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
Topics: Administration, Oral; Animals; Aspirin; Atherosclerosis; Cardiovascular Agents; Cholecystolithiasis; | 2012 |
Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
Topics: Aspirin; Dose-Response Relationship, Drug; Dyslipidemias; Flushing; Humans; Hypolipidemic Agents; Ni | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Atheroscler | 2006 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
Topics: Aspirin; Drug Combinations; Dyslipidemias; Health Services Needs and Demand; Humans; Hydroxymethylgl | 2007 |
[Peripheral arterial disease--an underappreciated clinical problem].
Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi | 2008 |
10 trials available for aspirin and Dyslipidemia
| Article | Year |
|---|---|
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Dysli | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Topics: Administration, Oral; Adult; Aged; Aspirin; Delayed-Action Preparations; Dose-Response Relationship, | 2009 |
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cohort Studies; Diabetes Mellitus; Dose-Response Rel | 2010 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem | 2010 |
Assessment of the Siksika chronic disease nephropathy-prevention clinic.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bl | 2013 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; | 2014 |
22 other studies available for aspirin and Dyslipidemia
| Article | Year |
|---|---|
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2 | 2020 |
Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Atherosclerosis; Dyslipidemias; Hep G2 Cells; Human | 2020 |
Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Dyslipidemias; F | 2021 |
Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Beijing; Blood Glucose; Cholesterol, LDL; Cross-Sectional S | 2018 |
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Coronary Disease; Di | 2018 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; | 2019 |
Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs).
Topics: Arrhythmias, Cardiac; Aspirin; Benzhydryl Compounds; Bradycardia; Computer Simulation; Databases, Ch | 2013 |
Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Weight; Bone and Bones; | 2013 |
Concurrent coxibs and anti-platelet therapy unmasks aspirin-exacerbated respiratory disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2 Inhibitors; Dyslipi | 2013 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Ca | 2015 |
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc | 2015 |
Effects of low-dose aspirin in subjects with dyslipidemia.
Topics: Adult; Aspirin; C-Reactive Protein; Cholesterol, LDL; Convalescence; Coronary Angiography; Coronary | 2016 |
Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aspirin; Case-Control Studies; Dyslipidemias; Female; Hu | 2017 |
Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetic Angiopathies; Dyslipidemias | 2010 |
Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Apolipoproteins E; Arterioles; Aspirin; Blo | 2010 |
[Myocardial infarction in the young adult--retrospective analysis of cases compile at the University Hospital of Dakar].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Contraceptive | 2010 |
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?
Topics: Adult; Aged; Alleles; Aspirin; Drug Resistance; Dyslipidemias; Female; Gene Frequency; Genotype; Hum | 2005 |
Evaluating and treating cardiometabolic risk factors: a case discussion.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Dyslipidemias; Exercise; Female; Heart Dise | 2006 |
The rate of checking urine microalbumin and aspirin primary prevention in type 2 DM.
Topics: Albuminuria; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hyp | 2006 |
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets; | 2007 |
[Prescription patterns for antilipidemic drugs in a group of Colombian patients].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antihypertensive Agents | 2008 |